Welcome to Markets Desk, your midday read on what's moving and why.
The valuation gap between big tech and the broader market has effectively closed, and Goldman Sachs is telling clients that's worth paying attention to. After a punishing stretch for names like Nvidia and the semis, the SOXX sitting twenty-three percent off its highs, the relative premium that justified owning mega-cap tech over everything else has largely evaporated. Goldman's read is that the selloff has created a genuine re-entry point, and with Amazon, Alphabet, Meta, Microsoft, and Oracle collectively posting over eight hundred thirty billion dollars in capital expenditure commitments, the underlying demand thesis for semiconductors remains structurally intact.
Shifting to currencies, the yen is getting a meaningful reprieve after what appears to be coordinated U.S. and Japanese intervention. The pair has pulled back to one hundred fifty-seven from just above one hundred sixty-three, which had been a forty-year low for the yen. Markets are watching closely whether this holds or whether intervention simply buys Tokyo time without addressing the rate differential driving the weakness.
And in pharma, reported merger talks between AstraZeneca and Bristol-Myers Squibb are moving both stocks in opposite directions, with AstraZeneca lower and Bristol-Myers higher. Analysts are openly questioning the strategic logic, and that skepticism is telling.
That's the tape. Markets Desk, signing off the floor.
